LONDON, UK and VALENCIA, Spain – June 2, 2026 – Coulter Partners, the global expert building leadership teams for Health, Science and Technology innovation businesses, successfully led a search for Quibim and is pleased to announce the placement of Itta MacNevin as Chief Business Officer (CBO).
We have an exciting opportunity to take on a key leadership role as Facilities Manager at Mills & Reeve's Cambridge office.
The role
Xampla is seeking a Business Development and Sales Lead (Licensees, Mills and Coaters) to drive commercial growth and take full ownership of how we scale our coatings business globally.
This is about more than sales delivery: it’s about shaping our commercial strategy, building deep partnerships across the paper coatings value chain, and positioning Xampla as a trusted partner for sustainable materials innovation.
ELRIG’s Drug Discovery 2026 is back at London’s Excel, and as Europe’s leading drug discovery and life sciences conference, it will have scientific tracks covering topics including Next Generation biophysics, microbes to medicines, multiomics, AI in compound discovery and in experimental design, and bioconjugation approaches in oncology.
• Drug Discovery 2026 returns to ExCeL London from 14–15 October to celebrate 20 years of collaboration and inclusion
• Keynote programme includes presentation from Dr Sam Barrell CBE and panel discussion with Dr Anne Phelan, Dr Jason Mellad, Prof Sir Mene Pangalos and Prof Raghib Ali OBE
• Key topics include next-generation biophysics, microbes to medicines, multiomics, AI in compound discovery and experimental design, and bioconjugation approaches in oncology
Launched in 2017, the UK DRI stands as a beacon of scientific innovation, representing an unprecedented £300 million investment in dementia research—the largest of its kind in UK history. The purpose of the UK DRI is to transform the outlook for people living with or at risk of neurodegenerative conditions through research.
Applications are invited for a Research Associate in oligodendrocyte and neuroimmune epigenomics to join the lab of Dr Alexi Nott (https://nottgroup.com/index.html) in the UK DRI at Imperial.
About Vernalis
Working within our fully equipped research laboratories in Cambridge, our established group of scientists are world leaders in multiple hit-ID technologies and structure-based drug discovery.
Our scientists develop and apply lead generation and structure-based methods to solve problems in drug discovery and have generated cell active compounds and development candidates against targets in multiple therapeutic areas including oncology, neurodegeneration, anti-infectives and inflammation.
About Vernalis
Working within our fully equipped research laboratories in Cambridge, our established group of scientists are world leaders in fragment and structure-based drug discovery.
Our scientists develop and apply fragment and structure-based methods to solve problems in drug discovery and have generated cell active lead compounds and development candidates against targets in oncology, neurodegeneration, anti-infectives and inflammation.
Introduction to the role: